PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Mucositis - chemotherapy / radiotherapy induced (Tranexamic acid - Mucositis - chemotherapy / radiotherapy induced)

Records returned : 6 (on 20 Apr 2025 at 08:45:52). .

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
02.11.00
12.03.01
Tranexamic acid
Mucositis - chemotherapy / radiotherapy induced
Red
Formulations :
  • Mouthwash
  • Soluble tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
5% mouthwash - unlicensed product. Used in line with St Luke's SACT protocols
02.11.00
12.03.01
Mucositis - chemotherapy / radiotherapy induced
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
SASH - Tablets used to make a mouthwash (off-label use). Use in line with St Luke's SACT protocols
Oral Film Forming Agents
Mucositis - chemotherapy / radiotherapy induced
Blue
Formulations :
  • Oromucosal gel
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Oncology request only. Primary Care prescribing may be appropriate in longer-term use and on request from oncology specialist team only. Ongoing use should be reviewed regularly to ensure that therapy is still required.
12.01.01
12.02.01
12.03.01
Betamethasone
Mucositis - chemotherapy / radiotherapy induced
Red
Formulations :
  • Soluble tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Patients on everolimus treatment. Used as a mouthwash, in line with St Luke's SACT protocols
02.03.02
04.07.03
12.03.01
15.02.01
Lidocaine
Mucositis - chemotherapy / radiotherapy induced
Red
Formulations :
  • Gel
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
2% gel
01.01.01
Aluminium and magnesium and oxetacaine
Mucositis - chemotherapy / radiotherapy induced
Red
Formulations :
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
As per guidance from St Luke's radiotherapy service for the management of immunotherapy-related adverse events: https://www.royalsurrey.nhs.uk/chemotherapy-policies-and-protocols?smbfolder=550
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More